311 related articles for article (PubMed ID: 26935576)
41. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
42. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
43. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
44. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
Wang J; Hao J; He N; Ji C; Ma D
Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
[TBL] [Abstract][Full Text] [Related]
45. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
[TBL] [Abstract][Full Text] [Related]
46. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
Jeryczynski G; Thiele J; Gisslinger B; Wölfler A; Schalling M; Gleiß A; Burgstaller S; Buxhofer-Ausch V; Sliwa T; Schlögl E; Geissler K; Krauth MT; Nader A; Vesely M; Simonitsch-Klupp I; Müllauer L; Beham-Schmid C; Gisslinger H
Am J Hematol; 2017 Sep; 92(9):885-891. PubMed ID: 28543356
[TBL] [Abstract][Full Text] [Related]
47. [Recent advances in the treatment of myelofibrosis].
Takenaka K
Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
[TBL] [Abstract][Full Text] [Related]
48. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
[TBL] [Abstract][Full Text] [Related]
49. [JAK2, CALR].
Ikejiri M
Rinsho Byori; 2017 Jan; 65(1):59-66. PubMed ID: 30695513
[TBL] [Abstract][Full Text] [Related]
50. [New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
[TBL] [Abstract][Full Text] [Related]
51. p.Y317H is a new
Eder-Azanza L; Hurtado C; Navarro-Herrera D; Aranaz P; Novo FJ; Vizmanos JL
Haematologica; 2017 Aug; 102(8):e328-e331. PubMed ID: 28473624
[No Abstract] [Full Text] [Related]
52. One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
Gangat N; Karrar O; Al-Kali A; Begna KH; Elliott MA; Wolanskyj-Spinner AP; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2024 Jan; 14(1):11. PubMed ID: 38238303
[TBL] [Abstract][Full Text] [Related]
53. Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2
Barosi G; Campanelli R; Catarsi P; De Amici M; Abbà C; Viarengo G; Villani L; Gale RP; Rosti V; Massa M
Leuk Res; 2020 Mar; 90():106319. PubMed ID: 32081398
[No Abstract] [Full Text] [Related]
54. Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.
Abbà C; Campanelli R; Catarsi P; Villani L; Abbonante V; Sesta MA; Barosi G; Rosti V; Massa M
PLoS One; 2019; 14(8):e0220189. PubMed ID: 31369569
[TBL] [Abstract][Full Text] [Related]
55. [Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis].
Yan X; Li B; Qin TJ; Qu SQ; Pan LJ; Wu JY; Liu D; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):15-20. PubMed ID: 33677863
[No Abstract] [Full Text] [Related]
56. Prevalence and phenotypes of
Cordua S; Kjaer L; Skov V; Pallisgaard N; Hasselbalch HC; Ellervik C
Blood; 2019 Aug; 134(5):469-479. PubMed ID: 31217187
[TBL] [Abstract][Full Text] [Related]
57. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
58. Recent advances in the diagnosis and management of primary myelofibrosis.
Takenaka K; Shimoda K; Akashi K
Korean J Intern Med; 2018 Jul; 33(4):679-690. PubMed ID: 29665657
[TBL] [Abstract][Full Text] [Related]
59. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
[TBL] [Abstract][Full Text] [Related]
60. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]